Global Cord Blood Banking Industry Report 2021: Industry Trends, Expansion Technologies, Profiles of Select Cord Blood Banks and Companies

News provided by

Jan 13, 2021, 14:45 ET

DUBLIN, Jan. 13, 2021 /PRNewswire/ -- The "Global Cord Blood Banking Industry Report 2021" report has been added to ResearchAndMarkets.com's offering.

From the early 1900s through the mid-2000s, the global cord blood banking industry proliferated with cord blood banks emerging in all major healthcare markets worldwide. From 2005 to 2010, the market reached saturation and stabilized. From 2010 to 2020, the market began to aggressively consolidate, creating both threats and opportunities within the industry.

Serious threats to the industry include low rates of utilization for stored cord blood, expensive cord blood transplantation procedures, difficulty educating obstetricians about cellular therapies, and an increasing trend toward industry consolidation. Opportunities for the industry include price efficiencies associated with scale and consolidation, accelerated regulatory pathways for cord blood and tissue-based cell therapies, and progress with ex vivo cellular expansion technologies.

Cord Blood Industry Trends

Within recent years, new themes have been impacting the industry, including the pairing of stem cell storage services with genetic and genomic testing services, as well as reproductive health services. Cord blood banks are diversifying into new types of stem cell storage, including umbilical cord tissue storage, placental blood and tissue, amniotic fluid and tissue, and dental pulp. Cord blood banks are also investigating means of becoming integrated therapeutic companies. With hundreds of companies offering cord blood banking services worldwide, the maturation of the market means that each company is fighting harder for market share.

Growing numbers of investors are also entering the marketplace, with M&A activity accelerating in the U.S. and abroad. Holding companies are emerging as a global theme, allowing for increased operational efficiency and economy of scale.Cryoholdco has established itself as the market leader within Latin America. Created in 2015, Cryoholdco is a holding company that controls over a quarter of a million stem cell units (approximately 270,000). It owns a half dozen cord blood banks, as well as a dental stem cell storage company.

Globally, networks of cord blood banks have become commonplace, with Sanpower Group establishing its dominance in Asia. Although Sanpower has been quiet about its operations, it holds 4 licenses out of only 7 issued provincial-level cord blood bank licenses in China. It has reserved over 900,000 cord blood samples in China, and its reserves amount to over 1.2 million units when Cordlife's reserves within Southeast Asian countries are included. This positions Sanpower Group and it's subsidiary Nanjing Cenbest as the world's largest cord blood banking operator not only in China and Southeast Asia but in the world.

The number of cord blood banks in Europe has dropped by more than one-third over the past ten years, from approximately 150 to under 100. The industry leaders in this market segment include FamiCord Group, which has executed a dozen M&A transactions, and Vita34, which has executed approximately a half dozen. Stemlab, the largest cord blood bank in Portugal, also executed three acquisition deals prior to being acquired by FamiCord. FamiCord is now the leading stem cell bank in Europe and one of the largest worldwide.

Cord Blood Expansion Technologies

Because cord blood utilization is largely limited to use in pediatric patients, growing investment is flowing into ex-vivocord blood expansion technologies. If successful, this technology could greatly expand the market potential for cord blood, encouraging its use within new markets, such as regenerative medicine, aging, and augmented immunity.

Currently, Gamida Cell, Nohla Therapeutics, Excellthera, and Magenta Therapeutics have ex vivo cord blood expansion products proceeding through clinical trials. Growing numbers of investors have also entered the cord blood banking marketplace, led by groups such as GI Partners, ABS Capital Partners & HLM Management, KKR & Company, Bay City Capital, GTCR, LLC, and Excalibur.

Key questions answered in this report are:

What are the strategies being considered for improving the financial stability of public cord blood banks?
What are the companion products proposed to be developed from cord blood?
How much is being spent on processing and storing a unit of cord blood?
How much does a unit of cryopreserved cord blood unit fetch on release?
Why do most public cord blood banks incur a loss?
What is the net profit margin for a private cord blood bank?
What are the prices for processing and storage of cord blood in private cord blood banks?
What are the rates per cord blood units in the U.S. and Europe?
What are the revenues from cord blood sales for major cord blood banks?
Which are the different accreditation systems for cord blood banks?
What are the comparative merits of the various cord blood processing technologies?
What is to be done to increase the rate of utilization of cord blood cells in transplantations?
Which TNC counts are preferred for transplantation?
What is the number of registered clinical trials using cord blood and cord tissue?
How many clinical trials are involved in studying the expansion of cord blood cells in the laboratory?
How many matching and mismatching transplantations using cord blood units are performed on an annual basis?
What is the share of cord blood cells used for transplantation from 2000 to 2020?
What is the likelihood of finding a matching allogeneic cord blood unit by ethnicity?
Which are the top ten countries for donating cord blood?
What are the diseases targeted by cord blood-derived MSCs within clinical trials?

Profiles of Select Cord Blood Banks and Companies

AllCells
AlphaCord LLC
Americord Registry, Inc.
Be The Match
Biocell Center Corporation
BioEden Group, Inc.
Biovault Family
Cell Care
Cell-Save
Cells4Life Group, LLP
Center for International Blood and Marrow Transplant Research (CIBMTR)
Cord Blood Center Group
Cord Blood Registry (CBR)
Cordlife Group, Ltd.
CordVida
Core23 Biobank
Crio-Cell International, Inc.
Crioestaminal
Cryo-Cell International, Inc.
CryoHoldco
Cryoviva Biotech Pvt. Ltd
European Society for Blood and Bone Marrow Transplantation (EBMT)
FamiCord Group
GeneCell International
Global Cord Blood Corporation
HealthBaby Hong Kong
HEMAFUND
Insception Lifebank
LifebankUSA
LifeCell International Pvt. Ltd.
Maze Cord Blood Laboratories
MiracleCord, Inc.
New England Cord Blood Bank, Inc.
New York Cord Blood Center (NYBC)
PacifiCord
ReeLabs Pvt. Ltd.
Smart Cells International, Ltd.
Stem Cell Cryobank
StemCyte, Inc.
Transcell Biolife
ViaCord
Vita 34 AG
World Marrow Donor Association (WMDA)
Worldwide Network for Blood & Marrow Transplantation (WBMT)

For more information about this report visit https://www.researchandmarkets.com/r/amvb5q

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets